Results 131 to 140 of about 94,605 (281)

Reviewer #1 (Public review): An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome

Pratibha Thakur, Martin Lackinger, Anastasia Diamantopoulou, Sneha Rao, Yijing Chen, Khakima Khalizova, Annie Ferng, Curt Mazur, Holly Kordasiewicz, Robert J Shprintzen, Sander Markx, Bin Xu, Joseph A Gogos   +12 more
openalex   +1 more source

Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides

, 2007
Liutao Du, Julianne M. Pollard, Richard A. Gatti   +2 more
openalex   +1 more source

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects [PDF]

, 2017
Rosie Z. Yu, Rudy Gunawan, Richard S. Geary, Steven G. Hughes, Scott P. Henry, Yanfeng Wang   +5 more
openalex   +1 more source

PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation

Cancer Science, EarlyView.
PSMD12, located on the frequently amplified 17q region in LUAD, is upregulated in tumors and associated with poor prognosis and advanced stage. Functional studies revealed that PSMD12 promotes cell proliferation and G2/M transition by inhibiting CDK1 ubiquitination and stabilizing CDK1.
Yuya Ono, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Koshi Mimori   +14 more
wiley   +1 more source

Structure-activity relationship of an antisense oligonucleotide-two Cu(II) complex conjugate as an artificial ribonuclease [PDF]

, 2008
D. Mukoguchi, Satoshi Sakamoto, Hiromitsu Takayama, Mitsuru Kitamura, H. Inoue   +4 more
openalex   +1 more source

In‐Tumor CRISPR‐Cas9 Knockout Screening and Novel Therapy Development for Malignant Transformation of Ovarian Teratoma

Cancer Science, EarlyView.
We conducted an in vivo genome‐wide CRISPR‐Cas9 knockout screen using MTMCT‐derived cells to identify genes essential for tumor growth. SOD1 emerged as a key therapeutic target, and its inhibition suppressed tumor proliferation by disrupting redox homeostasis, both in vitro and in PDX models. ABSTRACT Malignant transformation of mature cystic teratoma (
Satoshi Tamauchi, Kosuke Yoshida, Wang Xinyuan, Atsushi Nakagawa, Akira Yokoi, Nobuhisa Yoshikawa, Kaoru Niimi, Yusuke Yamamoto, Hiroaki Kajiyama   +8 more
wiley   +1 more source

Systemic distribution of tricyclo-DNA antisense oligonucleotide following intratracheal instillation in the mouse. [PDF]

NAR Mol Med
Laurent J, Deramaudt TB, Cloix R, Robin V, Beley C, Garcia L, Bonay M.   +6 more
europepmc   +1 more source

Non‐Coding RNAs in Breast Cancer Radioresistance: Mechanisms, Functional Roles and Translational Potentials

Cell Proliferation, EarlyView.
Non‐coding RNAs (ncRNAs) regulate breast cancer radioresistance via cell cycle, DNA repair and tumour microenvironment pathways. Targeting ncRNAs (e.g., HOTAIR and miR‐155) with RNA‐based therapies (ASOs and CRISPR) shows promise but faces delivery challenges.
Xiaohui Zhao, Yuting Qiu, Jie Chen, Danni Wang, Zairui Wang, Shuang Ma, Yimin Liu, Guoying Liu, Zhuofei Bi   +8 more
wiley   +1 more source

Antisense oligonucleotide therapies for monogenic disorders. [PDF]

Med Genet
Krey-Grauert I, Ferro I, Wagner M.
europepmc   +1 more source

RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs [PDF]

, 2020
Sarah Bajan, György Hutvàgner
openalex   +1 more source